Skip to main content
. 2016 Sep 29;6:34497. doi: 10.1038/srep34497

Figure 3. TAK1 inhibitor 5Z-7 suppresses NF-κB, JNK and p38 activation in OA chondrocytes and synoviocytes.

Figure 3

(a,b) Detection of the activation level of NF-κB, JNK and p38 pathways by (a) western blotting and (b) luciferase reporter assay in primary rat chondrocytes treated with IL-1β with or without 5Z-7 at indicated time points. (c,d) Detection of the activation level of NF-κB, JNK and p38 pathways by (c) western blotting and (d) luciferase reporter assay in primary rat synoviocytes treated with IL-1β with or without 5Z-7 at indicated time points. (e,f) Detection of the activation level of NF-κB, JNK and p38 pathways by (e) western blotting and (f) luciferase reporter assay in human OA chondrocytes treated with 5Z-7. (g,h) Detection of the activation level of NF-κB, JNK and p38 pathways by (g) western blotting and (h) luciferase reporter assay in human OA synoviocytes treated with 5Z-7. *P < 0.05, **P < 0.01.